氨苯蝶啶氢氯噻嗪的降血压效果提高患者的高血压。

文章的细节

引用

复制到剪贴板

他Z,涂W, Decker BS Erdel提单,埃克特GJ,赫尔曼RN,穆雷博士欧茨是的,普拉特JH

氨苯蝶啶氢氯噻嗪的降血压效果提高患者的高血压。

J创实习生地中海。2016年1月,31 (1):30-6。doi: 10.1007 / s11606 - 015 - 3469 - 1。

PubMed ID

26194642 (在PubMed

]

文摘

背景:氨苯蝶啶、因为它的保钾特性,经常用于结合氢氯噻嗪治疗高血压患者(HCTZ)。通过抑制上皮钠通道(钠)皮质集合管、氨苯蝶啶减少钾的分泌,从而减少低钾血的风险。氨苯蝶啶是否有一个独立的影响血压(BP)并没有被很好的研究。目的:确定氨苯蝶啶提供了一个效果,进一步降低BP HCTZ患者。设计:我们进行了一项观察性研究使用电子病历数据从印第安纳州网络病人护理。受试者17291例的诊断高血压在2004年和2012年之间。主要措施:英国石油公司是主要的结果。我们之间的BP患者服用HCTZ相比,有或没有氨苯蝶啶,单独或与其他抗高血压药物相结合,通过使用一个倾向得分分析。对于每个药物组合,我们估计倾向分数(即。概率)的患者接受氨苯蝶啶使用逻辑回归模型。 Patients with similar propensity scores were stratified into subclasses and BP was compared between those taking triamterene or not within each subclass; the effect of triamterene was then assessed by combining BP differences estimated from all subclasses. KEY RESULTS: The mean systolic BP in the triamterene + HCTZ group was 3.8 mmHg lower than in the HCTZ only group (p < 0.0001); systolic BP was similarly lower for patients taking triamterene with other medication combinations. Systolic BP reduction was consistently observed for different medication combinations. The range of systolic BP reduction was between 1 and 4 mm Hg, depending on the concurrently used medications. CONCLUSIONS: In the present study, triamterene was found to enhance the effect of HCTZ to lower BP. In addition to its potassium-sparing action, triamterene's ability to lower BP should also be considered.

DrugBank数据引用了这篇文章

药物

氨苯蝶啶